Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Cardiology/Vascular Diseases Phase I
Belgium 
Details:
Hyloris will use the net proceeds of the Offering primarily to fund the development of new products and accelerate in-house R&D activities including HY-073 (IV acetylsalicylic acid).
Lead Product(s): Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HY-073
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Berenberg
Deal Size: $16.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 01, 2022
Details:
Hyloris currently envisages using the net proceeds of the offering to primarily fund the development of additional new product candidates including HY-073 and accelerate in-house R&D activities, including repurposing and analytical expertise.
Lead Product(s): Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HY-073
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Berenberg
Deal Size: $16.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 31, 2022
